Skip to main content
Top
Published in: Clinical and Experimental Nephrology 10/2020

01-10-2020 | Chronic Kidney Disease | Original article

The role of cigarette smoking on new-onset of chronic kidney disease in a Japanese population without prior chronic kidney disease: Iki epidemiological study of atherosclerosis and chronic kidney disease (ISSA-CKD)

Authors: Kenji Ito, Toshiki Maeda, Kazuhiro Tada, Koji Takahashi, Tetsuhiko Yasuno, Kosuke Masutani, Shigeaki Mukoubara, Hisatomi Arima, Hitoshi Nakashima

Published in: Clinical and Experimental Nephrology | Issue 10/2020

Login to get access

Abstract

Background

Studies regarding harmful effects of smoking on the new-onset of chronic kidney disease (CKD) have been limited. Thus, we collected and retrospectively studied 8 years of data from the annual health check-ups of the residents in Iki City (Nagasaki Prefecture, Japan).

Methods

From 2008 to 2016, 4540 adults were enrolled in the study. Information on smoking habits was obtained via a self-reported questionnaire. New-onset CKD was defined as a reduction of the estimated globular filtration rate (eGFR) to less than 60 mL/min/1.73 m2 and/or new-onset proteinuria during the follow-up examinations.

Results

During an average follow-up of 4.6 years, proteinuria developed in 218 people (10.4 per 1000 person-years) and eGFR decline to less than 60 mL/min/1.73 m2 was confirmed in 594 people (28.3 per 1000 person-years) including 53 who showed both proteinuria and eGFR reduction (2.8 per 1000 person-years). In terms of proteinuria, current smokers showed a higher incidence than non-smokers (14.1 and 9.17 per 1000 person-years, respectively, p = 0.001), and a significantly high hazard ratio (HR) of 1.39 with a 95% CI of 1.01–1.92 in multivariable Cox’s proportional-hazard analyses. The tendency was more drastic among younger participants (p = 0.015 for trend): current smokers who were < 50 years old had a significantly higher HR of 2.55 with a 95% CI of 1.01–6.45 (p = 0.004) than non-smokers.

Conclusions

Smoking significantly increased the risk for new-onset of CKD based on proteinuria development in a Japanese population without CKD, and the association was more predominant in the younger population.
Literature
17.
go back to reference Group Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kideney Int. 2013;3(1):1–150. Group Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work. KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease. Kideney Int. 2013;3(1):1–150.
19.
go back to reference Obesity Examination Committee of Criteria for 'Obesity Disease' in Japan. New criteria for 'obesity disease' in Japan. Circ J. 2002;66(11):987–92.CrossRef Obesity Examination Committee of Criteria for 'Obesity Disease' in Japan. New criteria for 'obesity disease' in Japan. Circ J. 2002;66(11):987–92.CrossRef
20.
go back to reference Treatment Guide for Diabetes 2016–2017. BUNKODO; 2017. Treatment Guide for Diabetes 2016–2017. BUNKODO; 2017.
Metadata
Title
The role of cigarette smoking on new-onset of chronic kidney disease in a Japanese population without prior chronic kidney disease: Iki epidemiological study of atherosclerosis and chronic kidney disease (ISSA-CKD)
Authors
Kenji Ito
Toshiki Maeda
Kazuhiro Tada
Koji Takahashi
Tetsuhiko Yasuno
Kosuke Masutani
Shigeaki Mukoubara
Hisatomi Arima
Hitoshi Nakashima
Publication date
01-10-2020
Publisher
Springer Singapore
Published in
Clinical and Experimental Nephrology / Issue 10/2020
Print ISSN: 1342-1751
Electronic ISSN: 1437-7799
DOI
https://doi.org/10.1007/s10157-020-01914-8

Other articles of this Issue 10/2020

Clinical and Experimental Nephrology 10/2020 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.